Investigating the anti-TNBC potential of new quinazoline-based PAK4 inhibitors: design, synthesis and biological evaluation.
Results validate 11j as a promising lead for TNBC therapy, especially in combination with EGFR-targeted agents.
We have 2 of 16 papers
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
Results validate 11j as a promising lead for TNBC therapy, especially in combination with EGFR-targeted agents.
The identified conformational mechanism provides new insights into the dynamic regulation of CDK4 and suggests that stabilization of transient allosteric states represents a promising strategy for the rational design of next-generation CDK4 inhibitors with the potential to overcome resistance in breast cancer therapy.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.